scholarly journals Analysis of real‐world data to investigate the impact of race and ethnicity on response to PD ‐1 and PD‐L1 inhibitors in advanced non‐small cell lung cancers

2021 ◽  
Author(s):  
Kristin L. Ayers ◽  
Tommy Mullaney ◽  
Xiang Zhou ◽  
Jane J. Liu ◽  
Kyeryoung Lee ◽  
...  
Keyword(s):  
Real World ◽  
Race And Ethnicity ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
Lung Cancers ◽  
World Data ◽  
The Impact

Using real-world data to investigate time-dependent blood count response to PD-1 and PD-L1 inhibitors and its impact on survival in advanced non-small cell lung cancers.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21514-e21514
Author(s):  
Kristin Ayers ◽  
Zongzhi Liu ◽  
Meng Ma ◽  
Kyeryoung Lee ◽  
Scott Newman ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Real World ◽  
Blood Count ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data ◽  
Cell Counts ◽  
Count Response ◽  
The Impact

e21514 Background: Although some advanced non-small cell lung cancer (aNSCLC) patients respond favorably to immune checkpoint inhibitors, a larger portion either do not respond or experience negative side effects. At present, there is no consensus on how to best predict response to immunotherapy (IO) agents. Complete blood count (CBC) data have shown correlation with both progression and survival for patients treated with IO. However, previous studies have been relatively small, or did not focus on aNSCLC. Given CBCs are measured routinely for every patient throughout their course of therapy, we used real-world data (RWD) to assess the biomarker potential of CBCs in predicting response at the start and through the course of therapy. Methods: We performed a retrospective cohort study of 11,138 lung cancer patients treated at hospitals in the Mount Sinai Health System of whom 249 aNSCLC and were treated with anti-PD1/PD-L1 therapy. We extracted and harmonized medical record data using an automated abstraction engine and evaluated the impact of changes in CBCs, including eosinophils, lymphocytes, monocytes, neutrophils, red blood cells and platelets after treatment initiation. Time to treatment discontinuation (TTD) and overall survival (OS) were our clinical endpoints. Results: Abnormal baseline levels of monocytes, neutrophils, and red bloods cells were associated with OS; counts taken between 2-8 weeks were modestly to significantly associated with poorer OS, with hazard ratios ranging from 1.7-4.7. Most strikingly, neutrophil levels above 7 (HR = 4.3, p = 3.2*10−10, 95% CI = 2.7-6.7) and a neutrophil-to-lymphocyte ratio > 5 (HR = 3.4, p = 8.0*10−8, 95% CI = 2.2-5.4) were associated with poorer OS. For those with normal neutrophil levels at baseline, progressing to high levels at 2-8 weeks resulted in a hazard for OS of 5.0 (p = 4.4*10−8, 95% CI = 2.8-9.0). Those with progression are more likely to have high neutrophil levels at baseline, or an increase in neutrophil levels from normal to high levels between baseline and 2-8 weeks or 8-14 weeks. Our results remained consistent even after controlling for factors that may affect neutrophil levels including concurrent chemotherapy, administration of neutropenia medications, or concurrent infections. Repeating the analysis with TTD as the primary endpoint showed similar but less significant trends. Conclusions: RWD showed changes in blood cell counts after anti-PD1/PD-L1 therapy were associated with OS in aNSCLC and show promise as a predictive biomarker.

scholarly journals 1807P Real world data on 442 patients (p) with small cell lung cancer (SCLC) treated in the last ten years at Vall d’Hebron Hospital

2020 ◽  
Vol 31 ◽  
pp. S1044
Author(s):  
N. Saoudi Gonzalez ◽  
A. Navarro ◽  
G. Villacampa Javierre ◽  
A. Garcia-Alvarez ◽  
J.D.D. Assaf Pastrana ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data

scholarly journals Determining the Comparative Value of Pharmaceutical Risk-Sharing Policies in Non–Small Cell Lung Cancer Using Real-World Data

2019 ◽  
Vol 22 (3) ◽  
pp. 322-331 ◽  
Author(s):  
Marscha S. Holleman ◽  
Carin A. Uyl-de Groot ◽  
Stephen Goodall ◽  
Naomi van der Linden
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Risk Sharing ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data

ADJUVANT CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER IN ELDERLY PATIENTS: REAL-WORLD DATA ON TOLERANCE AND SAFETY

2019 ◽  
Vol 10 (6) ◽  
pp. S45
Author(s):  
M. Blasi ◽  
J. Kuon ◽  
M.E. Eichhorn ◽  
H. Bischoff ◽  
C. Wiedemann ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Elderly Patients ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data

scholarly journals EP1.04-31 Immunotherapy in Advanced Non-Small Cell Lung Cancer Previously Treated: Real World Data

2019 ◽  
Vol 14 (10) ◽  
pp. S973-S974
Author(s):  
F. Ferreira Pereira ◽  
A.R. Lopes ◽  
A. Cruz ◽  
M. Cassiano ◽  
A. Rosinha ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data ◽  
Previously Treated

scholarly journals P1.01-01 ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea

2018 ◽  
Vol 13 (10) ◽  
pp. S458
Author(s):  
B.C. Ahn ◽  
S. Park ◽  
S.W. Lim ◽  
H.R. Kim ◽  
M.H. Hong ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data

Using real world data to examine outcomes in immunotherapy-treated patients with metastatic non-small cell lung cancer.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e21715-e21715
Author(s):  
Sierra Luciano ◽  
Christian Haudenschild ◽  
Seth Kuranz
Keyword(s):  
Overall Survival ◽  
Real World ◽  
Small Cell ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Real World Data ◽  
Treatment Pathways ◽  
Time To Treatment ◽  
World Data

e21715 Background: Important questions have been raised about whether real world data (RWD) can be relied upon to support clinical and regulatory decision-making. The aims of this study were to assess overall survival (OS), time-to-treatment (TTT), follow-up time, and treatment pathways in metastatic non-small cell lung cancer (mNSCLC) patients treated with programmed cell death protein 1 inhibitors (PD-1i). Methods: Two mNSCLC cohorts were identified in a US based EMR network. To explore treatment pathways, patients had to have an advanced (stage 3/4) diagnosis of NSCLC confirmed by a tumor registry record. A line of treatment (LOT) was defined as a PD-1i or chemotherapy taken within 30 days. OS, time to treatment, and follow-up time were also calculated. In another cohort patients had to have at least one PD-1i (pembrolizumab, nivolumab, durvalumab, or atezolizmab) and an oncology treatment within 3 months of an advanced stage diagnosis. OS was calculated using Kaplan-Meier analysis and stratified by time after nivolumab approval, quarter of PD-1i initiation, and line of therapy of first PD-1i. Patient characteristics were defined by ICD, CPT, LOINC, and RxNorm terminology. Results: Median overall survival was found to be 213 days (IQR 109, 425.25). In the treatment pathways analysis, 58.3% of patients started on a non-PD-1i chemotherapy as an initial line of treatment for mNSCLC. PD-1i was the most common second line treatment and 41.4% of patients who started on a non-PD-1i therapy switched to a PD-1i as their second line therapy. Median time from advanced diagnosis to PD-1i inhibitor initiation (9.6 months (IQR 3.45, 21.45)) and median structured follow-up times from advanced diagnosis (21.87 months (IQR 11.94, 38.97)) and from inhibitor initiation (8.71 months (3.06, 17.26)) were comparable to results found in other RWD. Conclusions: Overall survival, time to treatment, and other outcomes were consistent with comparable RWD sources, (Stewart M, 2019; Sean K 2018) regardless of treatment timeframe. We demonstrated that our real world evidence based approach provides a robust method for analyzing clinical outcomes, supporting the validity of real world data to complement clinical trials and inform clinical decisions.

scholarly journals PS02.15 Evaluating the Uptake of Newly Marketed Drugs Using Real-World Data: An Example of Anti-PD-1s in Advanced Non-Small Cell Lung Cancer

2017 ◽  
Vol 12 (11) ◽  
pp. S1569-S1570
Author(s):  
K.M. Sheffield ◽  
Y.E. Zhu ◽  
Y. Fang ◽  
K.B. Winfree ◽  
G. Cuyun Carter ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Real World ◽  
Small Cell ◽  
Small Cell Lung ◽  
Real World Data ◽  
World Data
Sign in / Sign up

Export Citation Format

Share Document